These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 14644115)

  • 1. Prevention of prostate cancer with finasteride: US/European perspective.
    Thompson IM; Klein EA; Lippman SM; Coltman CA; Djavan B
    Eur Urol; 2003 Dec; 44(6):650-5. PubMed ID: 14644115
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PCPT: Evidence that finasteride reduces risk of most frequently detected intermediate- and high-grade (Gleason score 6 and 7) cancer.
    Kaplan SA; Roehrborn CG; Meehan AG; Liu KS; Carides AD; Binkowitz BS; Heyden NL; Vaughan ED
    Urology; 2009 May; 73(5):935-9. PubMed ID: 19328538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of prostate cancer for patients receiving finasteride: results from the Prostate Cancer Prevention Trial.
    Thompson IM; Pauler Ankerst D; Chi C; Goodman PJ; Tangen CM; Lippman SM; Lucia MS; Parnes HL; Coltman CA
    J Clin Oncol; 2007 Jul; 25(21):3076-81. PubMed ID: 17634486
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Finasteride improves the sensitivity of digital rectal examination for prostate cancer detection.
    Thompson IM; Tangen CM; Goodman PJ; Lucia MS; Parnes HL; Lippman SM; Coltman CA
    J Urol; 2007 May; 177(5):1749-52. PubMed ID: 17437804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of short-term finasteride on apoptotic factors and androgen receptors in prostate cancer cells.
    Bass R; Perry B; Langenstroer P; Thrasher JB; Dennis KL; Tawfik O; Holzbeierlein J
    J Urol; 2009 Feb; 181(2):615-9; discussion 619-20. PubMed ID: 19091346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The influence of finasteride on the development of prostate cancer.
    Thompson IM; Goodman PJ; Tangen CM; Lucia MS; Miller GJ; Ford LG; Lieber MM; Cespedes RD; Atkins JN; Lippman SM; Carlin SM; Ryan A; Szczepanek CM; Crowley JJ; Coltman CA
    N Engl J Med; 2003 Jul; 349(3):215-24. PubMed ID: 12824459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of finasteride on the sensitivity of PSA for detecting prostate cancer.
    Thompson IM; Chi C; Ankerst DP; Goodman PJ; Tangen CM; Lippman SM; Lucia MS; Parnes HL; Coltman CA
    J Natl Cancer Inst; 2006 Aug; 98(16):1128-33. PubMed ID: 16912265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection bias due to the effect of finasteride on prostate volume: a modeling approach for analysis of the Prostate Cancer Prevention Trial.
    Cohen YC; Liu KS; Heyden NL; Carides AD; Anderson KM; Daifotis AG; Gann PH
    J Natl Cancer Inst; 2007 Sep; 99(18):1366-74. PubMed ID: 17848668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-grade prostate cancer and finasteride.
    Lebdai S; Bigot P; Azzouzi AR
    BJU Int; 2010 Feb; 105(4):456-9. PubMed ID: 19930174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial.
    Lucia MS; Epstein JI; Goodman PJ; Darke AK; Reuter VE; Civantos F; Tangen CM; Parnes HL; Lippman SM; La Rosa FG; Kattan MW; Crawford ED; Ford LG; Coltman CA; Thompson IM
    J Natl Cancer Inst; 2007 Sep; 99(18):1375-83. PubMed ID: 17848673
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term effects of finasteride on prostate specific antigen levels: results from the prostate cancer prevention trial.
    Etzioni RD; Howlader N; Shaw PA; Ankerst DP; Penson DF; Goodman PJ; Thompson IM
    J Urol; 2005 Sep; 174(3):877-81. PubMed ID: 16093979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessing benefit and risk in the prevention of prostate cancer: the prostate cancer prevention trial revisited.
    Klein EA; Tangen CM; Goodman PJ; Lippman SM; Thompson IM
    J Clin Oncol; 2005 Oct; 23(30):7460-6. PubMed ID: 16157937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The Prostate Cancer Prevention Trial (PCPT). Relevance for clinical practice].
    Schmitz-Dräger BJ; Fischer C; Bismarck E; Dörsam HJ; Lümmen G
    Urologe A; 2007 Oct; 46(10):1364, 1366-8, 1370. PubMed ID: 17874228
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate cancer prevention and finasteride.
    D'Amico AV; Barry MJ
    J Urol; 2006 Nov; 176(5):2010-2; discussion 2012-3. PubMed ID: 17070238
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tissue Effects in a Randomized Controlled Trial of Short-term Finasteride in Early Prostate Cancer.
    Kim J; Davis JW; Klein EA; Magi-Galluzzi C; Lotan Y; Ward JF; Pisters LL; Basler JW; Pettaway CA; Stephenson A; Li Ning Tapia EM; Efstathiou E; Wang X; Do KA; Lee JJ; Gorlov IP; Vornik LA; Hoque AM; Prokhorova IN; Parnes HL; Lippman SM; Thompson IM; Brown PH; Logothetis CJ; Troncoso P
    EBioMedicine; 2016 May; 7():85-93. PubMed ID: 27322462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate cancer chemoprevention: update of the prostate cancer prevention trial findings and implications for clinical practice.
    Sarvis JA; Thompson IM
    Curr Oncol Rep; 2008 Nov; 10(6):529-32. PubMed ID: 18928669
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between variants in genes involved in the immune response and prostate cancer risk in men randomized to the finasteride arm in the Prostate Cancer Prevention Trial.
    Winchester DA; Till C; Goodman PJ; Tangen CM; Santella RM; Johnson-Pais TL; Leach RJ; Xu J; Zheng SL; Thompson IM; Lucia MS; Lippman SM; Parnes HL; Isaacs WB; De Marzo AM; Drake CG; Platz EA
    Prostate; 2017 Jun; 77(8):908-919. PubMed ID: 28317149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estimated impact of the Prostate Cancer Prevention Trial on population mortality.
    Unger JM; Thompson IM; LeBlanc M; Crowley JJ; Goodman PJ; Ford LG; Coltman CA
    Cancer; 2005 Apr; 103(7):1375-80. PubMed ID: 15739207
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Implications of the prostate cancer prevention trial: a decision analysis model of survival outcomes.
    Lotan Y; Cadeddu JA; Lee JJ; Roehrborn CG; Lippman SM
    J Clin Oncol; 2005 Mar; 23(9):1911-20. PubMed ID: 15774783
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Finasteride as a chemopreventive agent in prostate cancer: impact of the PCPT on urologic practice.
    Goetzl MA; Holzbeierlein JM
    Nat Clin Pract Urol; 2006 Aug; 3(8):422-9. PubMed ID: 16902518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.